Trials / Recruiting
RecruitingNCT06672718
A Study of SPY002-091 in Healthy Volunteers
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of SPY002-091 in Healthy Participants
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 56 (estimated)
- Sponsor
- Spyre Therapeutics, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
This is a Phase 1, randomized, double-blind, placebo-controlled, single- dose, first in human safety, tolerability, and pharmacokinetic study of SPY002-091 in healthy participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SPY002-091 | Experimental |
| OTHER | Placebo | Placebo |
Timeline
- Start date
- 2024-11-26
- Primary completion
- 2026-02-18
- Completion
- 2026-06-22
- First posted
- 2024-11-04
- Last updated
- 2025-08-17
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06672718. Inclusion in this directory is not an endorsement.